Abbott Laboratories (ABT) — Analysis Summary
Abbott Laboratories (ABT) has a market cap of $201.83B with year-over-year revenue growth of +5.7%. Net margin stands at 14.7%. The stock trades at a P/E ratio of 32.2.
Key Takeaways
- Revenue changed +5.7% year-over-year
- Net margin of 14.7%
- P/E ratio of 32.2
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, ABT posted revenue growth of +5.7% and trades at a P/E of 32.2.
Abbott Laboratories (ABT)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
115,000
Headquarters
ABBOTT PARK, IL
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$2.52
Dividend Yield
2.16%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.